Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1528115 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $4.97Day −3.12%Mkt cap $771M1Y +99.6%Off 52W high −30.8%Vol (1Y) 79.9%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,361 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest19.2% of sh out |
| Days to cover5.7d |
| 13F net flow (QoQ)+5.46% |
| Top-10 13F concentration49.4% |
| Next report (est.)2026-08-09 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$196.5M |
| ROE−81.9% |
| ROIC−116.6% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−1.0% |
| 1Y+99.6% |
| 3Y+54.8% |
| 5Y−77.3% |
| Since incept. (ann.)−29.5% |
Total return through 2026-07-28 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)79.9% |
| Ann. volatility (3Y)85.8% |
| Sharpe (1Y)1.26 |
| Sharpe (3Y)0.59 |
| Max drawdown (1Y)−35.1% |
| Max drawdown (3Y)−82.3% |
| Beta (3Y vs SPY)2.36 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Redmile Group, LLC | 14.5M | $81M | 9.38% | +44.8% |
| BlackRock, Inc. | 10.9M | $61M | 7.05% | +22.1% |
| FMR LLC | 10.6M | $59M | 6.86% | +4.0% |
| BVF INC/IL | 8.7M | $48M | 5.61% | −4.7% |
| STATE STREET CORP | 6.9M | $38M | 4.46% | +48.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.0M | $33M | 3.84% | new |
| Bain Capital Life Sciences Investors, LLC | 5.2M | $29M | 3.36% | −0.7% |
| Bellevue Group AG | 5.2M | $29M | 3.33% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 100.5% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 23,443,455 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.23 | — | — | — |
| 2025-09-30 | 2025-11-10 | −$0.37 | — | — | — |
| 2025-06-30 | 2025-08-14 | −$0.34 | — | — | — |
| 2025-03-31 | 2025-05-12 | −$0.37 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-09 is ESTIMATED from filing cadence (median gap 94d) — not company-confirmed.
